ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©µËÎı󡢡¢³Âºì²¨ºÍ³Ì·¼ÍŶÓÒÔºËÈÊΪÖÎÁưеãÍØÕ¹ÁË¡°ÀÏÒ©¡±rDNAת¼ÒÖÖÆ¼ÁCX5461µÄÐÂÓÃ;

¸å¼þȪԴ£º£ºÒ©Ñ§Ôº£¨ÉîÛÚ£© ±à¼­£º£ºÖ£Áú·É¡¢¡¢Íõ¶¬Ã· ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±³Âºì²¨£©ºËÈÊÊÇϸ°ûºËÖÐÒ»¸öÖ÷ÒªµÄÑÇϸ°û½á¹¹£¬£¬ÆäÖ÷Òª¹¦Ð§ÊÇת¼ºËÌÇÌåRNA (Ribosomal RNA, rRNA) ºÍ×é×°ºËÌÇÌå¾ÞϸÑÇ»ù¡£¡£µ«½üÄêµÄÑо¿·¢Ã÷ºËÈÊ»¹¼ÓÈëÁ˶àÖÖÖ÷ÒªµÄÉúÎïѧÀú³Ì£¬£¬ºÃ±Èϸ°ûÖÜÆÚµ÷¿Ø¡¢¡¢Ï¸°ûÐàÂõ¡¢¡¢Ï¸°ûÓ¦¼¤·´Ó³ÒÔ¼°ÒÅ´«ÐÔ¼²²¡µÈ¡£¡£µ«ºËÈÊÊÇ·ñ¿ÉÒÔ×÷ΪҩÎï×÷Óðе㻹±£´æÕùÂÛ£¬£¬ÏÖÔÚ»¹Ã»ÓÐÒÔºËÈÊΪ°ÐµãµÄÖÎÁÆÒ©Îï±»Åú×¼ÉÏÊС£¡£

2021Äê3Ô£¬£¬ngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©µËÎıó½ÌÊÚ¡¢¡¢³Âºì²¨¸±½ÌÊںͳ̷¼¸±½ÌÊÚÒÔÅäºÏͨѶ×÷ÕßÔÚEMBO Molecular Medicine (JCR 1Çø£¬£¬Ó°ÏìÒò×Ó12.1)½ÒÏþÁËÌâΪ¡°NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant development¡±µÄÎÄÕ (DOI: 10.15252/emmm.202012834)¡£¡£¸ÃÑо¿·¢Ã÷Ò»¸öºËÈʶ¨Î»µÄÂѰ׸´ºÏÌåNF45/ NF90¿ÉÒÔͨ¹ýµ÷¿ØºËÌÇÌåDNA£¨Ribosomal DNA£¬£¬ rDNA£©×ªÂ¼Ó°ÏìTϸ°ûµÄÔöÖ³ºÍ»î»¯¡£¡£¾­µäµÄTϸ°û»î»¯ÐźÅͨ·Ϊ¡°calcineurin-NFAT¡±ÐźÅͨ·¡£¡£ÔڻÐźŴ̼¤Ï£¬£¬calcineurin (CaN)±»¼¤»î£¬£¬CaN¶ÔNFAT È¥Á×Ëữ£¬£¬NFAT´Óϸ°ûÖÊת¶¨Î»µ½Ï¸°ûºËÖУ¬£¬²¢Á¬Ïµµ½IL-2Æô¶¯×ÓÇøÓòµÄARRE2ÐòÁÐÔª¼þÉÏ£¬£¬¼¤»îIL-2µÈϸ°ûÒò×ÓµÄת¼£¬£¬½ø¶ø¼¤»îTϸ°û¡£¡£Æ÷¹ÙÒÆÖ²¿ªÕ¹ÖÁ½ñ£¬£¬ÒÆÖ²Æ÷¹ÙµÄÉúÑÄ¡¢¡¢ÊÖÊõ¼°Êõºó´¦ÀíÒÑÈÕÒæ³ÉÊì,ÊÜÕß´æ»îÂÊÓÐËùÔö¸ß£¬£¬µ«ÒÆÖ²ÇãÔþ·´Ó³ÈÔÈ»ÊÇÍþвÊÜÕߺã¾Ã´æ»îµÄÖ÷ÒªÒòËØ¡£¡£ÏÖÔÚÆ÷¹ÙÒÆÖ²¿Æ³£ÓõĻ·æß¾úËØA¼°FK506¾ÍÊÇͨ¹ýÒÖÖÆ ¡°calcineurin-NFAT¡± Tϸ°û»î»¯ÐźÅͨ·Æð×÷Óᣡ£¶øÔÚ´ËÏîÑо¿ÖУ¬£¬Ñо¿Õß·¢Ã÷µ±Tϸ°û»î»¯Ê±£¬£¬NFAT²»µ«ÔÚºËÖÊÖе÷¿ØIL-2µÈϸ°ûÒò×ӵıí´ï£¬£¬Í¬Ê±²¿·ÖNFATÒ²»á½øÈëµ½ºËÈÊÖÐÓëNF45/NF90¸´ºÏÎïÏ໥×÷Ó㬣¬Á¬ÏµTϸ°ûrDNA»ùÒòÆô¶¯×ÓÉϵÄARRE2-likeÐòÁУ¬£¬Ð­Í¬Ôö½ørDNAת¼½ø¶ø¼¤»îTϸ°û(ͼ1)¡£¡£½øÒ»²½Ñо¿·¢Ã÷ÔÚСÊóÐÄÔàºÍƤ·ôÒÆÖ²ÇãÔþÄ£×ÓÖУ¬£¬ÒÔ¼°ÁÙ´²ÉöÒÆÖ²T ϸ°û½éµ¼µÄÇãÔþ·´Ó³£¨TCMR£©»¼ÕßµÄÑù±¾ÖÐrDNAת¼²úÆ·(pre-rRNA)µÄˮƽ¾ùÊÇÉý¸ßµÄ¡£¡£¾Ý´Ë£¬£¬Ñо¿Õß½«Ò»ÖÖrDNAÌØÒìÐÔת¼ÒÖÖÆ¼ÁCX5461Ó¦ÓÃÔÚСÊ󯤷ôºÍÐÄÔàÒÆÖ²Ä£×ÓÖУ¬£¬¾ªÏ²µÄ·¢Ã÷CX5461Ïà¹ØÓÚÁÙ´²³£ÓÃÒ©ÎïFK506Äܹ»¸üÓÐÓÃÑÓÉìÒÆÖ²ÎïµÄ´æ»îʱ¼ä£¬£¬²¢ÇÒ¾ßÓиüµÍµÄ¶¾¸±×÷Óᣡ£CX5461ÊÇÉúÎïÖÆÒ©¹«Ë¾Senhwa BiosciencesÓÚ2020Äê±»FDAÅú×¼¿É¿ªÕ¹ÓÃÓÚÖÎÁÆÐ¯´øBRCA2»òPALB2Í»±äµÄʵÌåÁö»¼ÕßIbÆÚÁÙ´²ÊÔÑéµÄÒ»¸öfirst-in-classÒ©Îï¡£¡£×ÛºÏÒÔÉÏ£¬£¬´ËÑо¿Õ¹ÏÖÁËÒ»ÖÖTϸ°û»î»¯µÄȫзÖ×Ó»úÖÆ£¬£¬·¢Ã÷Á˺ËÈÊ¿É×÷ΪÃâÒßÒÖÖÆ¼Á¿ª·¢µÄае㣬£¬²¢Àֳɽ«Ò»¸ö¿¹°©¡°ÀÏÒ©¡±CX5461µÄ˳Ӧ֢À©Õ¹µ½ÃâÒßÒÖÖÆµÄÁìÓò¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ1. NFATºÍNF45 / NF90ЭͬÔö½ørDNAת¼ºÍTϸ°û»î»¯µÄʾÒâͼ

¿ËÈÕ£¬£¬¸ÃÍŶӽøÒ»²½Î§ÈƺËÈÊÕâÒ»°Ðµã£¬£¬ÁªºÏÇ廪´óѧ»ÆÀ´Ç¿½ÌÊÚÍŶÓÔÚActa Pharmaceutica Sinica B (JCR 1Çø£¬£¬Ó°ÏìÒò×Ó11.4)ÉϽÒÏþÁËÌâΪ¡°PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-mutant leukemia¡±µÄÎÄÕ£¨https://doi.org/10.1016/j.apsb.2021.10.025£©¡£¡£Ìá³öÁËÕë¶ÔPHF6Í»±äÐͰ×Ѫ²¡µÄ¸öÐÔ»¯ÖÎÁÆ·½°¸¡£¡£Ö²ÎïͬԴ½á¹¹ÓòÖ¸ÂѰ×6£¨Plant homeodomain finger protein 6, PHF6£©µÄ·¢Ã÷Ô´ÓÚ¶Ô¡°²®-¸£-À³ÈýÊÏ×ÛºÏÖ¢£¨Borjeson-Forssman-Lehmann syndrome, BFLS£©¡±µÄÑо¿¡£¡£BFLSÊÇÒ»ÖÖXȾɫÌåÁ¬ËøµÄ¼Ò×åÒÅ´«ÐÔ¼²²¡£¬£¬Æäµä·¶Ö¢×´ÎªÖжȻòÖØ¶ÈÖÇÁ¦·¢Óý³ÙÖͺÍÉíÌå»ûÐΡ£¡£Ëæºó£¬£¬¶à¸öÑо¿±¨µÀPHF6µÄÍ»±äÓëTϸ°û¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¡£¨T-cell acute lymphoblastic leukemia£¬£¬T-ALL£©ºÍ¼±ÐÔËèϵ°×Ѫ²¡£¡£¨acute myeloid leukemia£¬£¬AML£©µÄ±¬·¢ºÍ¿ªÕ¹Ò²Ç×½üÏà¹Ø¡£¡£Ç°ÆÚÑо¿Åú×¢PHF6ÊÇÒ»¸öϸ°ûºËÈʶ¨Î»ÂѰ×£¬£¬Òò´ËÕ¹ÏÖPHF6ÔÚºËÈÊÖÐʩչºÎÖÖ¹¦Ð§ÒÔ¼°ÆäÏêϸ·Ö×Ó»úÖÆ½«ÄÜÔö½øÎÒÃǶ԰×Ѫ֢±¬·¢µÄÃ÷È·£¬£¬Í¬Ê±ÎªÔ¤·ÀºÍÖÎÁÆPHF6Ïà¹ØµÄ°×Ѫ²¡ÌṩеÄ˼Ð÷ºÍÒªÁì¡£¡£

ÔÚÕâÏîÊÂÇéÖУ¬£¬Ñо¿Õß·¢Ã÷PHF6¾ßÓÐÁ½¸ö·Çµä·¶µÄPHD½á¹¹Óò£¬£¬¿ÉÒԽ鵼ÆäÓëºËÈÊȾɫÖÊ×éÂѰ×ÉϵÄH3K9me3ºÍH3K27me1Á¬Ïµ£¬£¬²¢½«×éÂѰ׼׻ù×ªÒÆÃ¸SUV39H1ÕÐļµ½ºËÈÊÖУ¬£¬Î¬³ÖºËÈÊrDNA»ùÒò×ùλȾɫÖʵÄÒìȾɫÖÊ״̬£¬£¬´Ó¶øÒÖÖÆrDNA»ùÒòµÄת¼ºÍºËÌÇÌåµÄ×é×°¡£¡£PHF6µÄÇóýµ¼ÖÂSUV39H1ÏòrDNA»ùÒòλµãµÄÕÙļïÔÌ­£¬£¬µ¼ÖºËÈÊÇøÓò×éÂѰ×H3K9me3ˮƽ½µµÍ£¬£¬²¢Ôö½ørDNAת¼¡£¡£Ñо¿ÕßÒ²¿¼²ìÁ˶àÖÖPHF6ÁÙ´²Í»±äÌåµÄ¹¦Ð§£¬£¬·¢Ã÷ÕâЩͻ±äÌåµÄºËÈʶ¨Î»ÄÜÁ¦»òʶ±ðºÍÁ¬ÏµºËÈÊÇøÓòH3K9me3µÄÄÜÁ¦Ï÷Èõ£¬£¬ÒÔÖÁÓÚÆäÕÐļSUV39H1µÄÄÜÁ¦½µµÍ£¬£¬µ¼ÖÂrDNAת¼»îÐÔÔöÌí¡¢¡¢ÌåÍâ°×Ѫ²¡Ï¸°ûÔöÖ³ºÍÌåÄÚСÊó°×Ѫ²¡ÒìÖÖÒÆÖ²ÎïÉú³¤£¨Í¼2£©¡£¡£¸üÖ÷ÒªµÄÊÇ£¬£¬ÔÚPHF6Í»±äµÄÁÙ´²AML»¼ÕßÑù±¾ÖÐÒ²ÊӲ쵽rRNAǰÌå·Ö×ӵıí´ïˮƽÏÔÖøÉý¸ß£¬£¬½øÒ»²½Ö¤ÊµÎúÌåÍâÑо¿Ð§¹û¡£¡£´ó¼ÁÁ¿°¢ÌǰûÜÕÊÇÖÎÁÆAML×î³£ÓõÄÖÎÁÆ·½°¸£¬£¬µ«³£ÓÉÓÚAMLϸ°û¶ÔÆäÄÍÒ©ÐÔÒÔ¼°´ó¼ÁÁ¿¸øÒ©Ôì³ÉµÄ»¼Õß²»ÄÍÊܶøÊ¹µÃÖÎÁÆÊ§°Ü¡£¡£±¾Ñо¿·¢Ã÷CX5461Äܹ»ÏÔÖø½µµÍPHF6¹¦Ð§È±Ê§µÄU937 AMLϸ°û¶Ô°¢ÌǰûÜÕµÄÄÍÒ©ÐÔ¡£¡£ ×ÜÖ®£¬£¬´ËÑо¿Õ¹ÏÖÁËPHF6 ½«¼×»ù×ªÒÆÃ¸ SUV39H1 ÕÙļµ½°×Ѫ²¡µÄºËÈÊÇøÓò´Ó¶øÒÖÖÆrDNAת¼µÄ·Ö×Ó»úÖÆ£¬£¬Í¨¹ý¸Ã»úÖÆÎª PHF6 Í»±äÐͰ×Ѫ²¡ÌṩÁËÒ»ÖÖÓÐÔ¶¾°µÄ¸öÐÔ»¯¾«×¼ÖÎÁÆ·½°¸¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ2. PHF6 ʶ±ðºÍÁ¬ÏµºËÈÊÇøÓò×éÂѰ×H3K9me3£¬£¬ÕÐļ¼×»ù»¯×ªÒÆÃ¸SUV39H1 ½ø¶øÒÖÖÆ rDNA ת¼µÄʾÒâͼ

¸ÃÁ½ÏîÑо¿ÊÂÇé»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§ÃæÉÏÏîÄ¿¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿ºÍÉîÛÚÊпƴ´Î¯»ù´¡Ñо¿ÖصãÏîÄ¿µÄÖ§³Ö¡£¡£

¸ÃÍŶÓÒÀÍÐngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©Ò©Àíѧѧ¿Æ£¬£¬ÒÑÀֳɽ¨ÉèÏȽøµÄ¸ßͨÁ¿ÒÅ´«ÎÄ¿âɸѡÊÖÒÕÆ½Ì¨£¨CRISPR pooled gRNA libraries)£¬£¬²¢Ê¹ÓôËÊÖÒÕÕ¹ÏÖºÍÅжÏÁ˶à¸öÃâÒߺÍÖ×Áö¼²²¡µÄеÄÖÎÁưе㣬£¬ÍØÕ¹Á˶à¸ö¡°ÀÏÒ©¡±µÄÐÂÓÃ;¡£¡£½üÈýÄêÏà¹ØÐ§¹û»®·ÖÔÚCell Death & Differentiation £¨2021£©£¬£¬The Journal of Pathology £¨2020£©ºÍ Nature Communications£¨2019£©µÈÔÓÖ¾ÉϽÒÏþ¡£¡£

ÂÛÎÄÁ´½Ó£º£ºhttps://doi.org/10.1016/j.apsb.2021.10.025

¡¾ÍøÕ¾µØÍ¼¡¿